TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34427788
Drug: Medial to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medial to lateral (ML) dissection
Study: 34427788
Drug: ML group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ML group
Study: 34427990
Drug: Enasidenib 100
Normalized name: enasidenib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enasidenib 100 mg daily
Study: 34428076
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy with gemcitabine and cisplatin plus pembrolizumab
Study: 34428285
Drug: CC-486 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-486 (oral azacitidine) plus R-CHOP
Study: 34428992
Drug: rituximab monotherapy
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: rituximab monotherapy (R-mono)
Study: 34429088
Drug: Development of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Development of diet- and microbe-based therapies
Study: 34429090
Drug: G-YSQ (German
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-YSQ (German version of the Young Spine Questionnaire)
Study: 34429090
Drug: G-YSQ
Normalized name: Glyburide-Metformin
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-YSQ
Study: 34429332
Drug: Durvalumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab plus tremelimumab (tremelimumab 75 mg plus durvalumab 1500 mg once every 28 days for four cycles, then durvalumab alone every 28 days until disease progression)
Study: 34430604
Drug: IV Treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV Treprostinil (TRE) at an initial rate of 5 ng/kg/min, increased to 10 ng/kg/min every 30 min until reaching 80 ng/kg/min, administered for 12 hours.
Study: 34430790
Drug: Marzeptacog alfa
Normalized name: Marzeptacog alfa (activated)
DrugBank: Marzeptacog alfa (activated) (DB15278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marzeptacog alfa (activated) (MarzAA) 30 μg/kg SC daily for 50 days
Study: 34432206
Drug: Jianpi Bushen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jianpi Bushen Sequential Formula (JBSF)
Study: 34432679
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of INR/(CHE*platelet count)
Study: 34432679
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MELD/(CHE*platelet count)
Study: 34433303
Drug: UGN-102 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: UGN-102 (6 once-weekly instillations)
Study: 34433549
Drug: Dexamethasone intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone intravitreal implant 0.7 mg (DEX; Ozurdex)
Study: 34433593
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural treatment for childhood insomnia (CBT-CI) adapted for children with ASD (in-person or remote)
Study: 34433608
Drug: 12-month dietary
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month dietary intervention delivered via face-to-face motivational interviews, fortnightly motivational phone calls, monthly electronic pamphlets, quarterly newsletters and quarterly group meetings.
Study: 34433649
Drug: Lenalidomide Monotherapy
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide Monotherapy
Study: 34435395
Drug: BEO (bergamot
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEO (bergamot essential oil) cream (80 mg) applied trans-dermally twice a day for 4 weeks
Study: 34435395
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied trans-dermally twice a day for 4 weeks
Study: 34435552
Drug: Early PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early PET/CT scans on days 4 (D4) and 21 (D21) of cycle 1 (C1) of salvage therapy
Study: 34435897
Drug: Medical treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatments affecting bone metabolism
Study: 34436569
Drug: ABX464 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABX464 (150 mg daily for 4 weeks)
Study: 34439146
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) delivered as planned (60Gy in 15 fractions of 4.0Gy)
Study: 34439167
Drug: Fasting-Mimicking Diet
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting-Mimicking Diet (FMD) administered every three weeks/once a month, average of 6.3 cycles/patient
Study: 34439284
Drug: zPDX (zebrafish
Approvals — FDA: no, EMA: no, PMDA: no
Description: zPDX (zebrafish patient-derived xenograft) exposed to chemotherapy regimens
Study: 34439518
Drug: Deferoxamine (DFO)
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferoxamine (DFO) 40-60 mg/Kg/day
Study: 34440175
Drug: ABVD chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABVD chemotherapy regimen (doxorubicin, bleomycin, vinblastine, and dacarbazine)
Study: 34441840
Drug: Ciclesonide (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide (320 µg inhalation twice per day for 14 days)
Study: 34442202
Drug: Bright Light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright Light Therapy (BLT) sessions of 10,000 lux for 30 minutes, Monday through Friday, for 4 weeks.
Study: 34446044
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for colorectal cancer
Study: 34446378
Drug: Impaired daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impaired daily functioning
Study: 36116420
Drug: Ipilimumab 3
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 3 mg/kg intravenously
Study: 34452642
Drug: COPESS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: COPESS plus treatment as usual (TAU)
Study: 34453241
Drug: Lurbinectedin and
Normalized name: lurbinectedin
DrugBank: Lurbinectedin (DB12674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lurbinectedin and cisplatin combination with aprepitant (Group A)
Study: 34453241
Drug: Lurbinectedin and
Normalized name: lurbinectedin
DrugBank: Lurbinectedin (DB12674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lurbinectedin and cisplatin combination without aprepitant (Group B)
Study: 34453622
Drug: Electrical impedance
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electrical impedance tomography (EIT) with saline bolus (10 ml 10% NaCl injection) during a respiratory hold
Study: 34454047
Drug: Frameless unilateral
Normalized name: OCTINOXATE 2.0 mL in 100 mL TOPICAL CREAM [TRACELESS SKIN RESPONSIVE TINT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frameless unilateral radiosurgical ablation of the thalamic ventral intermediate nucleus to a maximum dose of 160 Gy
Study: 34454573
Drug: Inspiratory Muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory Muscle Training (IMT) sessions, exercising at 30% of MIP, two daily sessions for 3 weeks.
Study: 34454592
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care occupational therapy (OT)
Study: 34454787
Drug: ACAM2000 smallpox
Normalized name: ACAM2000 Smallpox (Vaccinia) Live Vaccine Powder for Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACAM2000 smallpox vaccine
Study: 34454787
Drug: Dryvax smallpox
Normalized name: Smallpox vaccine
DrugBank: Smallpox (Vaccinia) Vaccine, Live (DB14711)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dryvax smallpox vaccine
Study: 34455067
Drug: Dabrafenib 150
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib 150 mg twice daily and trametinib 2 mg once daily (cohort B)
Study: 34455067
Drug: Dabrafenib 150
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib 150 mg twice daily and trametinib 2 mg once daily (cohort C)
Study: 34457038
Drug: Oral masitinib
Normalized name: axitinib Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral masitinib (4.5 mg/kg/day)
Study: 34458717
Drug: Injection port
Normalized name: Injection Port
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection port of ported PVCs
Study: 38017564
Drug: Influenza A/Singapore/INFIMH-16-0019/2016(H3N2)-like
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza A/Singapore/INFIMH-16-0019/2016(H3N2)-like virus vaccine
Study: 34460083
Drug: NaIHS (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaIHS (50 mg ibuprofen, tid)
Study: 34461561
Drug: High eicosapentaenoic
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High eicosapentaenoic acid multinutrient supplement (1125 mg eicosapentaenoic acid, 441 mg docosahexaenoic acid, 330 mg magnesium, 7.5 mg vitamin E)
Study: 34462007
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion 1-2 μg/kg/min for 48 hours
Study: 34462189
Drug: GLS-010 (zimberelimab)
Normalized name: Anti-pd-1 monoclonal antibody gls-010
DrugBank: Zimberelimab (DB17505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLS-010 (zimberelimab) 240 mg, intravenous, once every 2 weeks until progression, death, unacceptable toxicity, or consent withdrawal
Study: 34462238
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone withdrawal
Study: 34462732
Drug: icosapent ethyl
Normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: icosapent ethyl (8 g daily for 3 days followed by 4 g daily for 11 days)
Study: 35921817
Drug: CD24Fc treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CD24Fc treatment
Study: 34463835
Drug: Therapeutic exercise
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic exercise (TE) intervention, delivered twice a week for 3 months, consisting of 1 hour of TE and 30 minutes of nutritional education
Study: 34464523
Drug: Equine-Assisted Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equine-Assisted Therapy
Study: 34465452
Drug: Prolonged cyclical
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged cyclical treatment regimen of dydrogesterone 10 mg 2 or 3 times daily between the 5th and 25th days of the menstrual cycle
Study: 34465452
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment regimen of dydrogesterone 10 mg 2 or 3 times daily
Study: 34465452
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment regimens (prolonged cyclical and continuous)
Study: 34465599
Drug: LY3300054/anti-TIM-3 combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3300054/anti-TIM-3 combination
Study: 34466766
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of immunotherapy, surgery, external beam radiation
Study: 34467254
Drug: Etrolizumab treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrolizumab treatment
Study: 34467476
Drug: gBRCA1/2 mutations
Approvals — FDA: no, EMA: no, PMDA: no
Description: gBRCA1/2 mutations in hormone receptor-positive MBC
Study: 34468953
Drug: Concurrent meningitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent meningitis and extra-cerebral IPD
Study: 34468953
Drug: Non-vaccine serotypes
Normalized name: SARS-COV-2 (COVID-19) vaccine, vector non-replicating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-vaccine serotypes
Study: 34468963
Drug: Antifungal therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifungal therapy (voriconazole alone or sequential/combined therapy)
Study: 34468963
Drug: Antifungal therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifungal therapy (voriconazole)
Study: 34468963
Drug: Optimal voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Optimal voriconazole regimen (loading dose, 200 mg twice daily; daily maintenance dose, 100 mg)
Study: 34469268
Drug: Treatments over
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatments over time
Study: 34470049
Drug: Venetoclax 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax 800 mg, Carfilzomib 70 mg/m2, Dexamethasone 40 mg
Study: 34470049
Drug: Venetoclax 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax 400 or 800 mg, Carfilzomib 27, 56, or 70 mg/m2, Dexamethasone 20 or 40 mg
Study: 34470489
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (EVT) with complete recanalization
Study: 34470614
Drug: Optimal BMI
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal BMI status and consistent multivitamin supplement intake
Study: 34472719
Drug: Anthracycline-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline-based chemotherapy (ABC)
Study: 34472769
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention program combined with oral antioxidant therapy (multivitamins, coenzyme Q10, omega-3, and oligo-elements) for 3 months
Study: 34473227
Drug: Machine learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine learning (ML) methods for classification of olfactory dysfunction
Study: 34473594
Drug: VARIVAX™ (Varicella
Approvals — FDA: no, EMA: no, PMDA: no
Description: VARIVAX™ (Varicella Virus Vaccine Live [Oka/Merck]) 0.5 mL, 2 doses 6 weeks apart
Study: 34474584
Drug: Thin-Strut Drug-Eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thin-Strut Drug-Eluting Stents (DES)
Study: 34474927
Drug: AVB-500 +
Normalized name: AVB-S6-500
DrugBank: Batiraxcept (DB17522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVB-500 + PAC (subgroup with no prior bevacizumab or AVB-500 trough levels >13.8 mg/L)
Study: 34475750
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) intravitreal implant 700 µg
Study: 34476122
Drug: Acute medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute medication overuse (AMO)
Study: 34476122
Drug: Simple analgesics,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple analgesics, combination analgesics, and opioids
Study: 34476229
Drug: Mobile health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile health (mHealth) intervention, details on dosage and duration not available
Study: 34476411
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of effusion and haemarthrosis
Study: 34476623
Drug: Therapist-report measure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-report measure of family therapy techniques (ITT-CEFT)
Study: 34477937
Drug: fedratinib 600
Normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: fedratinib 600 mg
Study: 34477937
Drug: cocktail of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: cocktail of digoxin 0.25 mg, rosuvastatin 10 mg, and metformin 1000 mg
Study: 34477993
Drug: Anti-TNF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF therapy (adalimumab, etanercept)
Study: 34478460
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated cholera vaccine
Study: 34478486
Drug: Gut microbial-derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gut microbial-derived indole compounds
Study: 34478487
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy (SCHOLAR-1)
Study: 34478825
Drug: Time Restricted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time Restricted Feeding (TRF) - 4-6 hours eating window, 18-20 hours fasting window daily
Study: 34479362
Drug: 75-g glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75-g glucose drink (OG)
Study: 34479925
Drug: MVA-BN-brachyury-TRICOM vaccine
Normalized name: MVA-BN-brachyury-TRICOM vaccine
DrugBank: MVA-BN-brachyury-TRICOM vaccine (DB17424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-BN-brachyury-TRICOM vaccine administered intravenously at three dose levels on days 1, 22, and 43.
Study: 34479925
Drug: MVA-BN-brachyury-TRICOM vaccine
Normalized name: MVA-BN-brachyury-TRICOM vaccine
DrugBank: MVA-BN-brachyury-TRICOM vaccine (DB17424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-BN-brachyury-TRICOM vaccine
Study: 34482353
Drug: Latency reversal
Normalized name: edrophonium chloride Injectable Solution [Reversol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latency reversal agents (LRA) - HDAC inhibitor
Study: 34483270
Drug: Topical insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical insulin (1 unit per mL), applied 4 times per day until resolution of persistent epithelial defect (PED) or ulcer.
Study: 34484101
Drug: Botulinum Toxin-A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum Toxin-A treatment, dosage and duration not specified
Study: 34484187
Drug: iNeo-Vac-P01, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: iNeo-Vac-P01, a personalized neoantigen-based peptide vaccine
Study: 34484431
Drug: Apatinib 500
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 500 mg orally each day continuously until unacceptable toxicity or tumor progression
Study: 34484473
Drug: Durvalumab after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab after concurrent chemoradiotherapy
Study: 34484473
Drug: Placebo after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo after concurrent chemoradiotherapy
Study: 34484473
Drug: Durvalumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab with subsequent immunotherapy removed
Study: 34484473
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with subsequent immunotherapy removed
Study: 34484887
Drug: Wait list/treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait list/treatment as usual (WL/TAU)
Study: 34485882
Drug: Locoregional therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional therapies (LRT) before liver transplantation (LT)
Study: 34487283
Drug: Optimal administered
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal administered radioactivity
Study: 34488662
Drug: Selinexor with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor with low dose dexamethasone
Study: 34489309
Drug: First-line treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line treatment with RAS/BRAF mutation analysis
Study: 34490414
Drug: B cell
Normalized name: B cell antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: B cell depleting therapies (BCDTs)
Study: 34490590
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with ticagrelor or prasugrel
Study: 34490604
Drug: Sodium restriction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium restriction (2 g of sodium/day)
Study: 34490604
Drug: Sodium restriction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium restriction (2 g of sodium/day) with sodium intake < 2500 mg/day
Study: 34490604
Drug: Control (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (3 g of sodium/day)
Study: 34491661
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (systolic blood-pressure target of 110 to less than 130 mm Hg)
Study: 34491661
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (systolic blood-pressure target of 130 to less than 150 mm Hg)
Study: 34491815
Drug: Cabozantinib 40
Normalized name: cabozantinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 40 mg once a day plus atezolizumab 1,200 mg intravenously every 3 weeks
Study: 34491815
Drug: Cabozantinib 60
Normalized name: cabozantinib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 60 mg once a day plus atezolizumab 1,200 mg intravenously every 3 weeks
Study: 34491815
Drug: Cabozantinib (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib (dosage not specified) plus atezolizumab 1,200 mg intravenously every 3 weeks in non-clear cell RCC
Study: 34492682
Drug: Dasatinib-dexamethasone induction
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib-dexamethasone induction followed by chemotherapy
Study: 34492703
Drug: CD19CAR T-cell
Normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19CAR T-cell therapy
Study: 34493347
Drug: Initial sUA
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial sUA < 6.0 mg/dL
Study: 34493347
Drug: Initial sUA
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial sUA between 6.0-6.8 mg/dL
Study: 34496148
Drug: Issuing 2-3
Normalized name: ALCOHOL 0.75 TOPICAL CLOTH [Care plus issue]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Issuing 2-3 months of pills at a time
Study: 34496270
Drug: Facial botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facial botulinum toxin injections
Study: 34496270
Drug: Cervical botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical botulinum toxin injections
Study: 34496904
Drug: TKA implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: TKA implants